This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Image courtesy of UCL Institute of Cardiovascular Science / James Tye milla1cf Tue, 12/19/2023 - 18:19 December 19, 2023 — A vest that can map the electrical activity of the heart in fine detail could potentially be used to better identify people at high risk of suddencardiacdeath , suggests a new study led by UCL researchers.
This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of suddencardiacdeath, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is associated with risk of suddencardiacdeath (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.
Hypertrophic cardiomyopathy (HCM) is associated with risk of suddencardiacdeath (SCD). Since approval in late 2012, the subcutaneous implantable cardioverter-defibrillator (SICD) has been used as an alternative to the traditional transvenous ICD (TV-ICD) for SCD prevention in HCM.
Implantable cardioverter defibrillator (ICD) prevents suddencardiacdeath (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.
Predictive factors of benefit from implantation of an implantable cardioverter-defibrillator (ICD) for primary prophylaxis of suddencardiacdeath in patients with nonischemic cardiomyopathy (NICM) have not been clarified.
Background Consensus guidelines support the use of implanted cardioverter-defibrillators (ICD) for primary prevention of suddencardiacdeath in patients with either non-ischaemic or ischaemic cardiomyopathy with left ventricular ejection fraction (LVEF) ≤35%.
Progressive decline across periods in mortality rates among patients with implantable cardioverter-defibrillator (ICD). Abstract Introduction Despite advancements in implantable cardioverter-defibrillator (ICD) technology, suddencardiacdeath (SCD) remains a persistent public health concern.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and suddencardiacdeath. channels, Connexin 43 and Wnt signalling, potentially modifying myocardial fibrosis.
Most patients with VT and structural heart disease preparing for ablation either have or are about to receive an implantable cardioverter defibrillator (ICD) shortly after the procedure to prevent suddencardiacdeath from recurrent ventricular arrhythmias (VA).
Background:Serum troponins and CK-MB (creatine kinase-MB) are readily detectable and reliable cardiac-specific biomarkers of subclinical myocardial injury. This study explores the roles of cTnI (cardiac troponin I) and CK-MB in hypertrophic cardiomyopathy (HCM).Methods:This Higher cTnI (per 0.05
The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). Ommen, MD, FACC , medical director of the Mayo Hypertrophic Cardiomyopathy Clinic and chair of the guideline writing committee.
In the subgroup with Class 3 of recommendation for implantable cardioverter defibrillator, patients with absolute LV-GLS ≤ 9% showed significantly worse prognosis than those with absolute LV-GLS > 9% (p =.002 Circulation, Volume 150, Issue Suppl_1 , Page A4142952-A4142952, November 12, 2024. vs -266.2; vs -264.9; 009), respectively.
Since its identification in 1981 its diagnosis has increased due to the advancements in cardiac imaging. It’s association with ventricular arrythmia (VA) and suddencardiacdeath (SCD) underscores the importance of its identification. Electrocardiogram (ECG) showed sustained monomorphic VT at a rate of 160 bpm.
Cardiovascular mortality, driven by suddencardiacdeath, is the main reason for dying while waiting for heart transplantation (HTx). Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF).
Tackling SCD was in God’s domain, until the brilliance of Dr. Michel Mirowski shrunk the defibrillator and implanted it under the chest in 1980. (Dr. 2020) The un-disputable fact is ischemic DCM has a target to treat, though it is termed as cardiomyopathy. SCD is the leading cause of mortality in heart failure. Reference 1.
Arrhythmogenic cardiomyopathy Long QT syndrome Hypertrophic cardiomyopathy. This episode self terminated before defibrillation was possible. The patient did not have a positive family history of epilepsy, suddencardiacdeath (SCD) or recurrent syncope. Learning Points: LQTS can have normal QTc.
The biopsy was consistent with cardiac sarcoidosis. She was given CRT-D (Cardiac Resynchronization Therapy-Defibrillator). SCD (suddencardiacdeath) from sarcoid heart disease is thought to be caused by either from high-grade AV block or VT. Medical treatment with oral steroids and methotrexate was started.
Suddencardiacdeath in cardiomyoptahies: incidence, risk factors and prevention. ABSTRACT Cardiomyopathies are a significant contributor to cardiovascular morbidity and mortality, mainly due to the development of heart failure and increased risk of suddencardiacdeath (SCD).
The study, titled " Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy " (TaRGET), will be led by the research team at PHRI and will involve collaboration with multiple organizations in addition to AMO Pharma including the Hearts in Rhythm Organization (HiRO).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content